Annual report pursuant to Section 13 and 15(d)

Revenue (Tables)

v3.21.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues During the years ended December 31, 2020 and 2019, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Years Ended December 31,
  2020 2019
AstraZeneca $ 8,308  $ 25,828 
Seagen 9,702  2,493 
Servier 11,313  15,048 
Other —  2,910 
Total Revenue $ 29,323  $ 46,279 
Schedule of Potential Milestone Payments
Under the Company´s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions) as of December 31, 2020:
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 1,111  $ 960 
Servier 247  221 
Seagen 764  450 
Total potential milestone payments $ 2,122  $ 1,631